Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation

EMBO Journal

Volumn 27, Issue 6, 2008, Pages 852-864

  Zhang, Zhuo ^a   Zhang, Ruiwen ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Apoptosis; DNA damage; MDM2; p53; PA28

Indexed keywords

NUCLEAR PROTEIN; PROTEIN MDM2; PROTEIN P53; PROTEIN PA28GAMMA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

ANIMALS; AUTOANTIGENS; BALB 3T3 CELLS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DOWN-REGULATION; ENZYME ACTIVATION; HCT116 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40949117250     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2008.25     Document Type: Article

References (30)

1. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602
2. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171
3. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315
4. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM (2007) Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell 26: 843-852
5. Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR, Lu H (2006) Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem 281: 24304-24313
6. Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, Lee SW (2007) Hzf determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 130: 624-637
7. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103: 3232-3237
8. Garber DW, Kulkarni KR, Anantharamaiah GM (2000) A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res 41: 1020-1026
9. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
10. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, Masuda T, Dawson S, Shimada Y, Mayer RJ, Fujita J (2005) The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8: 75-87
11. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208
12. Lane DP (1992) Cancer: p53, guardian of the genome. Nature 358: 15-16
13. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
14. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W (2003) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302: 1972-1975
15. Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R (2005) Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 65: 8200-8208
16. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW (2007) Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell 26: 831-842
17. Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW (2006) The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124: 381-392
18. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH (2003) Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3: 577-587
19. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206
20. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723
21. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, Prives C (2007) The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 26: 90-101
22. Poyurovsky MV, Prives C (2006) Unleashing the power of p53: lessons from mice and men. Genes Dev 20: 125-131
23. Rechsteiner M, Hill CP (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15: 27-33
24. Sui G, Affarel B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR, Shi Y (2004) Yin Yang 1 is a negative regulator of p53. Cell 117: 859-872
25. Tanaka T, Ohkubo S, Tatsuno I, Prives C (2007) hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 130: 638-650
26. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X (2006) Critical role for Daxx in regulating Mdm2. Nat Cell Biol 8: 855-862
27. Zhang R, Wang H, Agrawal S (2005) Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets 5: 43-49
28. Zhang Y, Xiong Y, Yarbrough WG (1998a) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734
29. Zhang Z, Clawson A, Realini C, Jensen CC, Knowlton JR, Hill CP, Rechsteiner M (1998b) Identification of an activation region in the proteasome activator REGalpha. Proc Natl Acad Sci USA 95: 2807-2811
30. Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003) Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100: 11636-11641